Senate Judiciary Committee pushes prescription drug cost reforms

Senate Judiciary Committee pushes prescription drug cost reforms
Senate targets drug prices

Lawmakers are renewing scrutiny of the pharmaceutical supply chain as pressure builds to curb high prescription drug prices for U.S. patients. The latest Senate Judiciary Committee hearing centers on whether stronger competition rules and greater transparency can limit the influence of pharmacy benefit managers and other intermediaries.

Highlights

  • Senate Judiciary Committee advanced six bipartisan bills targeting PBM opacity, patent gaming, pay-for-delay, and FDA-Patent Office coordination to reduce drug costs.
  • Chairman Chuck Grassley cited FTC staff reports and ongoing regulatory actions, urging close monitoring of PBM consent orders and new rules impacting drug price transparency.
  • Grassley called for passage of the Drug-price Transparency for Consumers Act, requiring drugmakers to disclose prices in direct-to-consumer ads to promote cost awareness.

Committee hearing targets supply chain practices

As reported by Senate Committee on the Judiciary, Chairman Chuck Grassley opened a hearing on prescription drug costs by arguing that hidden contracts, rebates, fees and payments across the supply chain make it difficult for patients and consumers to understand why medicines remain expensive.

Grassley said manufacturers, wholesalers, distributors, pharmacy benefit managers, insurers, employers and pharmacies all affect the final price of a prescription. He said anticompetitive and abusive tactics keep drug prices high, and called for bipartisan action to make medications more affordable.

He pointed to six bipartisan bills advanced by the committee last year that target practices including opaque PBM behavior, product hopping, patent games, sham citizen petitions, pay-for-delay deals and coordination issues between the FDA and the Patent Office. Grassley also noted that the Senate unanimously passed the Affordable Prescriptions for Patients Act in July and said the chamber should move the five remaining bills.

Grassley said PBMs have evolved from claims processors into powerful gatekeepers that influence which drugs patients can access, what patients pay and how pharmacies are reimbursed. He also said his two-year bipartisan insulin price gouging investigation, which he said was cited by the FTC, found that PBMs encourage manufacturers to raise list prices in exchange for larger rebates and favorable formulary placement.

Transparency debate expands to regulators and advertisers

Grassley said the FTC's interim staff reports on PBMs are useful, but he is still waiting for a full report with legislative recommendations. He added that he asked the FTC last month for an update on when Congress will receive that report, and said proposed consent orders involving major PBMs will need close monitoring to ensure they help patients.

He also referenced congressional action in February on PBM reform in Medicare Part D and the private insurance market, and said the Department of Labor implemented related regulation last month. Grassley said he is watching that rule and the Centers for Medicare and Medicaid Services' expected regulatory work next year to see whether the measures lower drug costs.

Beyond PBM oversight, Grassley urged Senate consideration of the Drug-price Transparency for Consumers Act, a bill he said is a priority for both him and Senator Dick Durbin. He argued that drugmakers advertising prescription medicines directly to the public should disclose prices so patients can ask about lower-cost alternatives before reaching the pharmacy counter.

Grassley framed the hearing as a broader review of the entire prescription drug supply chain, saying accountability must follow the decision maker and no participant should be able to hide behind the system's complexity. The panel is hearing from witnesses including a patient advocacy organization, a transparent cost-plus pharmacy co-founder, the Iowa Pharmacy Association, a health economist and the CEO of Illinois health clinics.

We recently wrote about proposed QPAM exemption changes from the U.S. Labor Department aimed at preventing disruptive retirement-plan investment unwinds.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.